RNLX News and Press, Renalytix AI plc From 06/09/23

LONDON and SALT LAKE CITY, June 09, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, toda...

LONDON and SALT LAKE CITY, June 05, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) will report its third quarter fiscal year 2023 financial results on Friday, June 9, 2023, before market open. The Company will host a corresponding conference call and live webcast to discuss the...

LONDON and CHICAGO, May 25, 2023 (GLOBE NEWSWIRE) -- Renalytix (NASDAQ: RNLX) (LSE: RENX) , the first company to develop and commercialize an artificial intelligence (AI) powered in-vitro diagnostic for kidney disease, has selected EVERSANA , a global leader in life-science commercializat...

Real-World Utility Data Demonstrates KidneyIntelX Optimizes Clinical Management in Early-Stage Chronic Kidney Disease Across Multiple Physician Specialties KidneyIntelX individualizes clinical decisions beginning at primary care where impacts of new therapies, blood pressure strategie...

In a clinical decision effectiveness study, KidneyIntelX classified more Black vs non-Black patients as high risk for progression of chronic kidney disease, resulting in increased prescription of SGLT2-inhibitor drug therapy Additional study results illustrate how KidneyIntelX is alig...

2023-03-30 12:20:03 ET Renalytix Plc (RNLX) Q2 2023 Earnings Conference Call March 30, 2023 08:30 A.M. ET Company Participants Peter DeNardo - CapComm Partners James McCullough - CEO O. James Sterling - CFO Thomas McLain - President Fergus Fleming - CTO ...

2023-03-30 07:16:11 ET Renalytix AI press release ( NASDAQ: RNLX ): Q2 GAAP EPS of -$0.14 in-line. Revenue of $1.2M (+42.9% Y/Y) misses by $0.08M . For further details see: Renalytix AI GAAP EPS of -$0.14 in-line, revenue of $1.2M misses by $0.08M

LONDON and SALT LAKE CITY, March 30, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, tod...

LONDON and SALT LAKE CITY, March 22, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced that it will report its second quarter and first half fiscal year 2023 financial results on Thursday, March 30, 2023, before market open. The Company will host a corresponding co...

2023-03-21 11:34:27 ET Shares Renalytix ( NASDAQ: RNLX ) lost ~17% on Tuesday to reach the lowest level in three months after announcing that the FDA delayed the review of the company’s De Novo marketing authorization application for the KidneyIntelX diagnostic plat...